Strong Q2 Results on the Back of Technology Exports and New Drugs
Single-Digit Operating Margins Excluding One-Off Gains
Profitability Defense and R&D Under Pressure in the Second Half

Major domestic traditional pharmaceutical companies achieved solid results in the second quarter of this year, thanks to inflows from technology export signing fees and robust growth of their main products. However, excluding temporary income from license agreements, their overall operating margins remain low, making the defense of profitability in response to drug pricing system reforms a key task for the second half of the year.


Despite Record-Breaking Results, the Pharmaceutical Industry Remains Cautious View original image

According to the pharmaceutical and biotech industry as of August 4, three out of the five leading pharmaceutical companies (Yuhan, Chong Kun Dang, Hanmi Pharmaceutical, Daewoong Pharmaceutical, and GC Green Cross) reported improved sales and profitability compared to the same period last year. Hanmi Pharmaceutical stood out the most. On a consolidated basis, Hanmi Pharmaceutical posted sales of 467.2 billion won and operating profit of 131.1 billion won in the second quarter, soaring by 29.3% and 116.9%, respectively. Both figures are the highest since the fourth quarter of 2015, driven by the recognition of a guaranteed license payment of USD 75 million (about 110 billion won) from the license agreement for the biologic candidate "Sunepegutide" with Eli Lilly.


Yuhan also set new all-time records, led by the performance of Leclaza. Its second-quarter sales rose 10.4% year-on-year to 639.5 billion won, surpassing the 600 billion won mark for quarterly sales for the first time. Operating profit increased 34.1% to 66.9 billion won. Technology-related revenue such as milestone payments from the start of commercialization of Leclaza in Europe amounted to 58.9 billion won alone.


Daewoong Pharmaceutical achieved record-high quarterly results solely through internally developed new drugs and export products, even without technology licensing income. In the second quarter, sales were 448.5 billion won and operating profit was 68.1 billion won, up 10.6% and 17.7% year-on-year, respectively. Sales of botulinum toxin Nabota surpassed the 10 billion won mark for the first time in a quarter, reaching 103.4 billion won, with exports alone accounting for 94.1 billion won, thus driving growth. Prescription sales of the new gastroesophageal reflux disease drug Fexuclu also supported results, rising 24.6% in outpatient clinics in the first half.


In contrast, Chong Kun Dang and GC Green Cross posted disappointing results in terms of profitability. Chong Kun Dang’s second-quarter sales rose 10.7% year-on-year to 475.4 billion won, maintaining top-line growth, but operating profit declined 10.1% to 19.9 billion won. This was due to increased sales of in-licensed novel drugs, which raised the proportion of merchandise sales and, consequently, the burden of cost of goods sold. At GC Green Cross, the exclusion of GC Green Cross Wellbeing (which was divested to the holding company) from consolidated subsidiaries led to declines in both sales and operating profit.


Although major pharmaceutical companies delivered strong second-quarter results aided by license income inflows, industry attention is now focused on the aftermath of the Ministry of Health and Welfare’s drug pricing system overhaul, which began in earnest on August 1. Through this reform, the government has significantly lowered the reimbursement standard for generic drugs under the National Health Insurance system.


Previously, the baseline price for generics was set at 53.55% of the original drug’s price, but with this reform, the rate has been reduced to 45%. In addition, products that fail to meet top-tier requirements—such as conducting their own clinical trials or using registered active pharmaceutical ingredients—will face even bigger reductions, with prices falling by up to 25.6% compared to the previous standard. For pharmaceutical companies, this creates a structure in which both sales and profits will inevitably decrease, even if the same amount of generics are sold.



Excluding one-off license income, the pure operating margins of most pharmaceutical companies still remain in the single digits. With a full-fledged generic price reduction, profitability of high-volume generic product groups is expected to deteriorate further, and cost pressures will intensify. There is growing concern throughout the pharmaceutical industry that the impact of these price cuts may lead to reduced investment in research and development (R&D) for new drug development.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing